The FDA's 2025 Draft Guidance is titled "Quality Management System Information for Certain Premarket Submission Reviews

This draft guidance describes a streamlined process for FDA reviewers to evaluate a manufacturer's QMS during premarket review, replacing the disconnected, "siloed" approach with a proactive use of QMS information to achieve a smoother, more effective review.

Key Drivers and Objectives

1. Alignment with International Standards: This guidance is a major step in implementing the Medical Device Single Audit Program (MDSAP) and aligning US regulations with international norms (ISO 13485:2016).
2. Enhanced Review Efficiency: By understanding the manufacturer's QMS upfront, reviewers can better assess the credibility of the design validation, risk management, and manufacturing data presented in the submission.
3. Risk-Based Approach: The level of QMS requested is tailored to the risk profile of the device and the manufacturer's regulatory history.
4. Proactive Problem Prevention: It shifts the focus from merely assessing the finished device design to also evaluating the system that creates and maintains it, aiming to prevent post-market issues.

Who and What Does It Apply To?

Applicability: The guidance is intended for certain premarket submissions, specifically:

• PMA (Premarket Approval Applications)
• PDP (Product Development Protocols)
• De Novo requests
• Premarket Report (for devices reviewed under the Breakthrough Devices Program)
• HDE (Humanitarian Device Exemptions) are also included.

Notably, it does not currently apply to 510(k) submissions. However, the principles may influence future FDA thinking for all device types.

Strategic Implications for Manufacturers

1. "Shift Left" for Quality: Quality system considerations must be integrated from the start of design and development, not treated as a post-design "check-the-box" activity.
2. Enhanced Documentation: Your Design History File (DHF) and Risk Management File must be meticulously maintained, as they now serve as direct inputs for regulatory submissions, not just internal audits.
3. Proactive Preparation: When preparing a PMA, De Novo, or similar submission, your team (RA, QA, R&D) must collaborate to curate QMS info demonstrating a controlled development process.
4. Potential for a Smoother Review: A well-prepared QMS info package boosts FDA reviewer confidence, reduces questions, and streamlines review by addressing manufacturing concerns early.
5. Increased Scrutiny on Risk Management: Your risk management process should be comprehensive, transparent, and integrated with design controls, as it will be the focus of the review.

Important Caveats

This is a DRAFT Guidance: As of its 2025 issuance, it is not final. The FDA is seeking public comments. The final version may have changes based on stakeholder feedback.

For more information, visit https://eemedicals.com/